Trial Profile
A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- 23 Oct 2012 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 16 Aug 2010 New trial record